Thomssen C - Search Results

1

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.

Degenhardt T, Fasching PA, Lüftner D, Müller V, Thomssen C, Schem C, Witzel I, Decker T, Tesch H, Kümmel S, Uleer C, Wuerstlein R, Hoffmann O, Warm M, Marschner N, Schinköthe T, Kates RE, Schumacher J, Otremba B, Zaiss M, Harbeck N, Schmidt M; PreCycle Investigators. Degenhardt T, et al. Among authors: thomssen c. Trials. 2023 May 17;24(1):338. doi: 10.1186/s13063-023-07306-z. Trials. 2023. PMID: 37198674 Free PMC article. Clinical Trial.

2

Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.

Thomssen C, Oppelt P, Jänicke F, Ulm K, Harbeck N, Höfler H, Kuhn W, Graeff H, Schmitt M. Thomssen C, et al. Anticancer Res. 1998 May-Jun;18(3C):2173-80. Anticancer Res. 1998. PMID: 9703780

3

Prognostic impact of tumor biological factors on survival in node-negative breast cancer.

Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Anticancer Res. 1998 May-Jun;18(3C):2187-97. Anticancer Res. 1998. PMID: 9703782

4

Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.

Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Br J Cancer. 1999 May;80(3-4):419-26. doi: 10.1038/sj.bjc.6690373. Br J Cancer. 1999. PMID: 10408848 Free PMC article.

5

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.

Harbeck N, Thomssen C, Berger U, Ulm K, Kates RE, Höfler H, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Breast Cancer Res Treat. 1999 Mar;54(2):147-57. doi: 10.1023/a:1006118828278. Breast Cancer Res Treat. 1999. PMID: 10424405

6

Long-term follow-up confirms prognostic impact of PAI-1 and cathepsin D and L in primary breast cancer.

Harbeck N, Alt U, Berger U, Kates R, Krüger A, Thomssen C, Jänicke F, Graeff H, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Int J Biol Markers. 2000 Jan-Mar;15(1):79-83. doi: 10.1177/172460080001500115. Int J Biol Markers. 2000. PMID: 10763146 Free article.

7

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

Jänicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, Sweep CG, Selbmann HK, Graeff H, Schmitt M; German N0 Study Group. Jänicke F, et al. Among authors: thomssen c. J Natl Cancer Inst. 2001 Jun 20;93(12):913-20. doi: 10.1093/jnci/93.12.913. J Natl Cancer Inst. 2001. PMID: 11416112 Clinical Trial.

8

Clinical relevance of the plasminogen activator inhibitor type 1--a multifaceted proteolytic factor.

Harbeck N, Krüger A, Sinz S, Kates RE, Thomssen C, Schmitt M, Jänicke F. Harbeck N, et al. Among authors: thomssen c. Onkologie. 2001 Jun;24(3):238-44. doi: 10.1159/000055086. Onkologie. 2001. PMID: 11455216 Review. English, German.

9

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. Harbeck N, et al. Among authors: thomssen c. Clin Cancer Res. 2001 Sep;7(9):2757-64. Clin Cancer Res. 2001. PMID: 11555589

10

Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.

Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, Jänicke F, Thomssen C. Harbeck N, et al. Among authors: thomssen c. Clin Breast Cancer. 2002 Aug;3(3):196-200. doi: 10.3816/CBC.2002.n.023. Clin Breast Cancer. 2002. PMID: 12196277 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

331 results

Search Page